Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,473
Recruiting: 1,285
Ph III recruiting: 130
Growth YoY: +6.4%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,641)

clinicaltrialsPublishedShowing 101–104 of 104 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05181501	A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)	not yet recruiting	Phase 1	20	Nanjing IASO Biotechnology Co., Ltd.INDUSTRY	1	Jan 6, 2022	clinicaltrials
NCT05091541	A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	not yet recruiting	Phase 1 / Phase 2	125	Nanjing IASO Biotechnology Co., Ltd.INDUSTRY	0	Oct 25, 2021